Colchicine in Moderate Symptomatic COVID-19 Patients

Inclusion criteria: * Males and females of least 18 years of age and can swallow tablets * Competent and willing to provide informed consent * Patient must have received a diagnosis of COVID-19 infection with positive RT-PCR for SARS CoV-2 within the last 3 days * Patients with moderate symptoms (According to National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID- 19).Version 7.0 .2020, DGHS, MOHFW, Government of the People's Republic of Bangladesh). Following features of moderate covid-19 must be present- 1. Fever or history of fever 2. Cough and /or Shortness of breath 3. Oxygen saturation 94% or more 4. Pneumonia -pulmonary consolidations on chest imaging (chest x ray or CT scan of chest) involving less than 50%of lungs 5. CRB 65 score 0 Exclusion criteria: * Pregnancy and breast-feeding * Known hypersensitivity to colchicine * Known chronic illness e.g hepatic failure, chronic kidney disease (eGFR\<30ml/min), decompensated heart failure, long QT syndrome (QTc \>450 msec.) * Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption * Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout) * Patient undergoing chemotherapy for cancer * Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.